Emerging hepatotoxicity biomarkers and their potential to improve understanding and management of drug-induced liver injury

Biomarkers of drug-induced liver injury (DILI) are essential for the diagnosis of severe cases of DILI in clinical trials and clinical practice, but the currently used biomarker paradigm detects damage after it has occurred and has limited prognostic value. The development of new biomarker strategie...

Descripción completa

Detalles Bibliográficos
Autores principales: Aubrecht, Jiri, Schomaker, Shelli J, Amacher, David E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979132/
https://www.ncbi.nlm.nih.gov/pubmed/24073687
http://dx.doi.org/10.1186/gm489
Descripción
Sumario:Biomarkers of drug-induced liver injury (DILI) are essential for the diagnosis of severe cases of DILI in clinical trials and clinical practice, but the currently used biomarker paradigm detects damage after it has occurred and has limited prognostic value. The development of new biomarker strategies that improve the diagnosis of DILI by providing increased specificity and/or by identifying individual patients who are at risk for DILI is therefore crucial. See related Research, http://genomemedicine.com/content/5/9/86

Ejemplares similares